Selective Janus Kinase Inhibition Preserves Interferon-Λ-mediated Antiviral Responses

Inflammatory diseases are frequently treated with Janus kinase (JAK) inhibitors to diminish cytokine signaling. These treatments can lead to inadvertent immune suppression and may increase the risk of viral infection. Tyrosine kinase 2 (TYK2) is a JAK family member required for efficient type I inte...

詳細記述

保存先:
書誌詳細
出版年:Sci Immunol
主要な著者: Schnepf, Daniel, Crotta, Stefania, Thamamongood, Thiprampai, Stanifer, Megan, Polcik, Laura, Ohnemus, Annette, Vier, Juliane, Jakob, Celia, Llorian, Miriam, Gad, Hans Henrik, Hartmann, Rune, Strobl, Birgit, Kirschnek, Susanne, Boulant, Steeve, Schwemmle, Martin, Wack, Andreas, Staeheli, Peter
フォーマット: Artigo
言語:Inglês
出版事項: 2021
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7610871/
https://ncbi.nlm.nih.gov/pubmed/33990378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciimmunol.abd5318
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料